237 related articles for article (PubMed ID: 15161771)
1. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
Tonelli J; Li W; Kishore P; Pajvani UB; Kwon E; Weaver C; Scherer PE; Hawkins M
Diabetes; 2004 Jun; 53(6):1621-9. PubMed ID: 15161771
[TBL] [Abstract][Full Text] [Related]
2. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
3. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
4. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
5. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
6. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
[TBL] [Abstract][Full Text] [Related]
7. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.
Satoh N; Ogawa Y; Usui T; Tagami T; Kono S; Uesugi H; Sugiyama H; Sugawara A; Yamada K; Shimatsu A; Kuzuya H; Nakao K
Diabetes Care; 2003 Sep; 26(9):2493-9. PubMed ID: 12941708
[TBL] [Abstract][Full Text] [Related]
8. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.
Boden G; Cheung P; Mozzoli M; Fried SK
Metabolism; 2003 Jun; 52(6):753-9. PubMed ID: 12800103
[TBL] [Abstract][Full Text] [Related]
9. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
Coletta DK; Sriwijitkamol A; Wajcberg E; Tantiwong P; Li M; Prentki M; Madiraju M; Jenkinson CP; Cersosimo E; Musi N; Defronzo RA
Diabetologia; 2009 Apr; 52(4):723-32. PubMed ID: 19169664
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Aso Y; Yamamoto R; Suetsugu M; Matsumoto S; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Diabet Med; 2007 Sep; 24(9):962-8. PubMed ID: 17509067
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
15. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.
Hammarstedt A; Pihlajamäki J; Graham TE; Kainulainen S; Kahn BB; Laakso M; Smith U
J Intern Med; 2008 Apr; 263(4):440-9. PubMed ID: 18324929
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
17. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.
Glintborg D; Frystyk J; Højlund K; Andersen KK; Henriksen JE; Hermann AP; Hagen C; Flyvbjerg A; Andersen M
Clin Endocrinol (Oxf); 2008 Feb; 68(2):165-74. PubMed ID: 17803698
[TBL] [Abstract][Full Text] [Related]
18. The effect of pioglitazone on the liver: role of adiponectin.
Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
